A Multi-Center Evaluation of the Long-Term Safety and Efficacy of SPK-8011 [Adeno-Associated Viral Vector With B-Domain Deleted Human Factor VIII Gene] in Males With Hemophilia A
Phase of Trial: Phase IV
Latest Information Update: 07 Sep 2018
At a glance
- Drugs SPK 8011 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Sponsors Spark Therapeutics
- 28 Aug 2018 Status changed from not yet recruiting to recruiting.
- 12 Jul 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.
- 16 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 May 2018.